DLBCL is the most common aggressive lymphoma worldwide (3), and overexpression of the oncogenes MYC, BCL2, and BCL6 (4–6) influences pathogenesis and prognosis (7–9). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.